Great Point Partners as of March 31, 2026
Portfolio Holdings for Great Point Partners
Great Point Partners holds 42 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Apogee Therapeutics (APGE) | 7.2 | $32M | 374k | 84.17 | |
| Vor Biopharma Com New (VOR) | 7.2 | $31M | 1.8M | 17.84 | |
| Zura Bio Class A Ord Shs (ZURA) | 5.8 | $25M | 4.2M | 5.95 | |
| Amylyx Pharmaceuticals (AMLX) | 5.6 | $24M | 1.8M | 13.90 | |
| Immunitybio Put Option (IBRX) | 5.3 | $23M | 3.0M | 7.67 | |
| Nektar Therapeutics Com New (NKTR) | 5.2 | $23M | 317k | 71.95 | |
| Sol-gel Technologies Shs New (SLGL) | 5.0 | $22M | 274k | 79.22 | |
| Alumis (ALMS) | 4.3 | $19M | 856k | 22.03 | |
| Bright Minds Biosciences Com New (DRUG) | 3.7 | $16M | 220k | 72.97 | |
| Annexon (ANNX) | 3.2 | $14M | 2.5M | 5.54 | |
| Kalvista Pharmaceuticals (KALV) | 3.1 | $14M | 675k | 20.13 | |
| Immunovant (IMVT) | 3.1 | $14M | 546k | 24.84 | |
| Jade Biosciences Com New (JBIO) | 3.1 | $14M | 965k | 14.05 | |
| Contineum Therapeutics Cl A (CTNM) | 2.4 | $11M | 800k | 13.06 | |
| Zenas Biopharma (ZBIO) | 2.4 | $10M | 524k | 19.55 | |
| Neurogene (NGNE) | 2.3 | $10M | 500k | 20.16 | |
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 2.1 | $9.3M | 500k | 18.64 | |
| Eliem Therapeutics (CLYM) | 2.1 | $9.1M | 1.3M | 6.85 | |
| Oruka Therapeutics (ORKA) | 2.1 | $9.0M | 183k | 49.05 | |
| Eupraxia Pharmaceuticals (EPRX) | 2.0 | $8.7M | 1.2M | 7.24 | |
| Vera Therapeutics Cl A (VERA) | 1.8 | $8.0M | 199k | 40.23 | |
| Evommune Com Shs (EVMN) | 1.7 | $7.5M | 325k | 22.99 | |
| Lb Pharmaceuticals Com Shs (LBRX) | 1.7 | $7.4M | 300k | 24.66 | |
| Compass Therapeutics (CMPX) | 1.6 | $7.1M | 1.4M | 5.29 | |
| Scynexis Com New (SCYX) | 1.6 | $6.9M | 7.6M | 0.92 | |
| Palisade Bio (PALI) | 1.4 | $6.0M | 3.4M | 1.75 | |
| Context Therapeutics (CNTX) | 1.3 | $5.9M | 2.2M | 2.62 | |
| Relmada Therapeutics (RLMD) | 1.3 | $5.9M | 842k | 6.96 | |
| Silence Therapeutics Ads (SLN) | 1.2 | $5.4M | 1.0M | 5.27 | |
| Unicycive Therapeutics Com New (UNCY) | 1.2 | $5.2M | 797k | 6.58 | |
| Tenax Therapeutics Com New (TENX) | 1.2 | $5.2M | 327k | 15.99 | |
| Promis Neurosciences Com Shs (PMN) | 1.1 | $4.7M | 371k | 12.70 | |
| Cullinan Oncology (CGEM) | 1.0 | $4.3M | 300k | 14.21 | |
| Immix Biopharma (IMMX) | 0.7 | $3.2M | 350k | 9.11 | |
| Rezolute Com New (RZLT) | 0.7 | $2.9M | 952k | 3.05 | |
| Pharvaris N V (PHVS) | 0.5 | $2.3M | 83k | 28.25 | |
| Humacyte (HUMA) | 0.5 | $2.3M | 3.8M | 0.61 | |
| Galectin Therapeutics Com New Call Option (GALT) | 0.5 | $2.2M | 800k | 2.79 | |
| Avalo Therapeutics Com New (AVTX) | 0.4 | $1.9M | 125k | 14.93 | |
| Alkermes SHS (ALKS) | 0.4 | $1.8M | 50k | 35.36 | |
| Anavex Life Sciences Corp Com New Call Option (AVXL) | 0.4 | $1.6M | 521k | 3.07 | |
| Ocuphire Pharma (IRD) | 0.3 | $1.5M | 324k | 4.55 |
